508 material Form 8-K filings that 423 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Par Pacific received indications from its lenders to increase its senior secured term loan by $100.0 million, to an aggregate initial principal of $650.0 million, with $641.750 million outstanding. The amendment is expected to be signed on or around November 25, 2024, and the company says the added funds will go to general corporate purposes, which means the company will carry more debt.
On November 18, 2024, lenders indicated commitments to raise the term loan by $100.0 million to $650.0 million initial principal.
Aggregate outstanding principal under the amended loan is $641.750 million.
Amendment No. 2 is expected to be executed on or around November 25, 2024, and take effect that day.
Proceeds will be used for general corporate purposes; the original loan dates from February 28, 2023, with Wells Fargo Bank as administrative agent.
Lancaster Colony Corporation, through subsidiary Marzetti Manufacturing Company, agreed on November 18, 2024 to buy a sauce and dressing production facility and related real estate in Atlanta, Georgia, from Winland Foods, Inc. The purchase price is $75 million in cash, as adjusted under the agreement, and the company intends to fund it with cash on hand. The deal is expected to close in the first quarter of 2025, subject to customary closing conditions.
Purchase price of $75,000,000 in cash, as adjusted under the Purchase Agreement, to be paid from cash on hand
Expected closing in the first quarter of calendar 2025
Buyer will manufacture certain products for Seller for up to twelve months after closing, a condition to completing the transaction
Buyer has agreed to offer employment to workers at the facility; the press release cites about 300,000 total square feet, about 250,000 designated for manufacturing
On November 15, 2024, Post Holdings announced it intends to redeem the remaining $464.9 million of its 5.625% senior notes due 2028 at 100.938% of principal, plus accrued interest, with a redemption date expected to be December 2, 2024. The company plans to fund the redemption with cash on hand, including net proceeds from its $600.0 million 6.25% senior notes due 2034 issued October 9, 2024. The filing also discloses stock-based awards to named executive officers approved November 12, 2024.
Redemption amount: 100.938% of the $464.9 million principal, plus accrued and unpaid interest, with a redemption date expected December 2, 2024
Funding: cash on hand, including net proceeds from the $600.0 million 6.25% senior notes due 2034 issued October 9, 2024
Executive awards: CEO Robert V. Vitale received 43,747 RSUs and 43,747 target PRSUs; PRSUs vest based on three-year relative TSR ranking
Plan change: Board approved the amended and restated 2021 Long-Term Incentive Plan on November 13, 2024; the share increase and extension to November 13, 2034 require shareholder approval
Protagonist said its Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies of icotrokinra in plaque psoriasis met their primary endpoints. Under a November 13, 2024 amendment to its collaboration with Janssen, the company has earned a $165 million milestone, which it expects to receive in Q1 2025, and the filing states the payment is not refundable. The filing does not provide revenue, profit or guidance figures.
ICONIC-LEAD: 64.7% of patients reached IGA 0/1 at week 16 on icotrokinra vs. 8.3% on placebo; 49.6% reached PASI 90 vs. 4.4% on placebo.
Amendment raised the Phase 3 milestone by $50 million to $165 million and eliminated $35 million and $15 million milestone payments, which accelerates them into the $165 million.
Company expects to receive the $165 million in Q1 2025 and remains eligible for up to $630 million in future milestones plus tiered royalties of 6-10% on worldwide net sales.
ADM reported third quarter 2024 GAAP net earnings attributable to the company of $18 million, or $0.04 per diluted share, compared with $821 million, or $1.52 per share, a year earlier. The results include a $461 million non-cash impairment charge on its Wilmar equity investment, and adjusted EPS was $1.09. ADM also filed restated financial statements for fiscal 2023 and the first two quarters of 2024, which it says did not affect consolidated results, and affirmed its full-year 2024 adjusted EPS range of $4.50 to $5.00.
Revenues were $19.9 billion, down from $21.7 billion in the prior-year quarter.
Total segment operating profit was $1,037 million, down 28% from $1,446 million.
Full-year 2024 adjusted EPS guidance of $4.50 to $5.00 was affirmed, not changed.
Fourth quarter AS&O segment operating profit is expected to be lower than a year earlier; Nutrition is expected to be higher than a year earlier but lower than the third quarter.
Molina Healthcare completed a private offering of $750 million of 6.250% senior unsecured notes maturing January 15, 2033, on November 18, 2024. The company reported net proceeds of approximately $740 million and plans to use them for general corporate purposes, which may include debt repayment, acquisitions, share repurchases and capital contributions to its health plan subsidiaries.
Notes: $750 million principal, 6.250% annual interest, paid semi-annually from July 15, 2025
Maturity date January 15, 2033; redeemable on or after January 15, 2028
Net proceeds approximately $740 million after fees and expenses
Notes are senior unsecured and not initially guaranteed by any subsidiaries
Associated Banc-Corp completed an underwritten public offering of 13,800,000 shares of common stock at $25.00 per share on November 18, 2024, with BofA Securities and J.P. Morgan Securities as underwriters. The underwriters also exercised in full their option to buy 1,800,000 additional shares on November 15, 2024. The company expects net proceeds of approximately $330.7 million after underwriting discounts and offering expenses, and the issuance increases the number of shares outstanding.
13,800,000 shares sold at $25.00 per share to the underwriters, with the offering completed on November 18, 2024
Underwriters exercised in full their option for 1,800,000 additional shares on November 15, 2024
Expected net proceeds of approximately $330.7 million after underwriting discounts and estimated offering expenses
Shares were sold under Form S-3 registration statement File No. 333-280004 and prospectus supplements dated November 14, 2024
Arlo Technologies entered a three-year, $45.0 million revolving credit agreement with HSBC Bank USA on November 14, 2024, maturing November 14, 2027. No amounts had been drawn as of the filing date, and the facility can be increased by up to an additional $30.0 million at the company's request, subject to conditions. The loans are secured by substantially all company assets and require the company to meet fixed charge coverage and net leverage covenants.
Revolving credit facility of up to $45.0 million, maturing November 14, 2027, with a $10.0 million letter of credit sublimit
Uncommitted accordion feature allows an increase of up to an additional $30.0 million, subject to conditions
Borrowings are secured by substantially all company assets; no amounts drawn as of the filing date
Covenants require a fixed charge coverage ratio of at least 1.50 to 1.00 and a total net leverage ratio not exceeding 3.00 to 1.00
AECOM reported fiscal fourth-quarter 2024 revenue of $4.1 billion, up 7% from a year earlier, with diluted EPS of $1.25 as reported and adjusted EPS up 26%. It guided fiscal 2025 adjusted EPS to $5.00 to $5.20 and raised its quarterly dividend 18% to $0.26 and its share repurchase authorization to $1 billion, which affects per-share returns for shareholders.
Q4 fiscal 2024 diluted EPS was $1.25 as reported, versus $0.24 a year earlier; adjusted EPS rose 26%
Full-year fiscal 2024 revenue was $16.1 billion, up 12%, and free cash flow was $708 million
Fiscal 2025 guidance includes adjusted EPS of $5.00 to $5.20 and adjusted EBITDA of $1,170 million to $1,210 million
Quarterly dividend raised to $0.26 from $0.22, payable January 17, 2025, to holders of record on January 2, 2025
Huntington Ingalls Industries completed a public offering of $1 billion in senior unsecured notes on November 18, 2024, split evenly between $500 million of 5.353% notes due 2030 and $500 million of 5.749% notes due 2035. The filing describes the notes' interest schedule, guarantees, and covenants, which add to the company's long-term debt obligations for shareholders.
$500 million of 5.353% Senior Notes mature January 15, 2030
$500 million of 5.749% Senior Notes mature January 15, 2035
Interest is paid semi-annually on January 15 and July 15, beginning July 15, 2025
Notes are guaranteed by certain domestic subsidiaries; U.S. Bank Trust Company, National Association, is trustee
American Healthcare REIT entered an at-the-market equity sales agreement allowing it to sell up to $500 million of common stock through a group of banks acting as agents or forward sellers. The filing does not say that any shares have been sold, and the company will not receive proceeds from shares borrowed by forward purchasers and sold through forward sellers.
Agreement dated November 18, 2024 covers up to $500 million aggregate gross sales price of common stock.
Agents may receive commissions of up to 2.0% of gross sales price of shares sold through them as agent.
Company intends to contribute net proceeds to its Operating Partnership for general corporate purposes, which may include repaying indebtedness.
On November 18, 2024, GameStop increased its board from five to six members and appointed Nathaniel Turner as a director, with a term expiring at the 2025 Annual Meeting. Turner is also CEO and Chairman of Collectors Holdings, whose Profession Sports Authenticator (PSA) division has a collaboration with GameStop, so the appointment adds a board seat tied to a business relationship. The filing says transactions under that collaboration have totaled approximately $1.53 million since it began in October 2024.
Board expanded from five to six members; Turner's term expires at the 2025 Annual Meeting of Stockholders.
Turner was not appointed to any board committees and will receive no compensation for serving as a director.
Turner is CEO and Chairman of Collectors Holdings, which entered a PSA collaboration with GameStop in October 2024.
Turner owns up to a 10% equity interest in PSA; approximate transaction value with GameStop since the collaboration began is $1.53 million.
CVS Health increased its board from 12 to 16 members on November 17, 2024, appointing Leslie Norwalk, Larry Robbins, Guy Sansone and Doug Shulman, after discussions with activist investor Glenview Capital Management. The company also entered a confidentiality agreement with Glenview that includes customary standstill and non-disparagement terms, and the filing describes compensation changes for two senior executives.
Board expanded from 12 to 16 members; Norwalk, Robbins, Sansone and Shulman appointed November 17, 2024
Company agreed to nominate all four for election at the 2025 annual meeting of stockholders
Glenview standstill restrictions remain in effect until 30 days before the stockholder nomination window for the 2026 annual meeting
Premium-priced stock options with grant date values of $12,000,000 for CEO J. David Joyner and $6,000,000 for Prem S. Shah, granted November 30, 2024
Broadstone Net Lease said its total estimated build-to-suit development commitments are now $246.5 million, to be funded through the second quarter of 2026, down from $418.8 million in its October 30, 2024 release. A prospective tenant for a large build-to-suit project in the pipeline changed its strategy after an unanticipated executive leadership change and chose not to proceed, including with the Company's transaction, which lowers the development growth pipeline shareholders had been counting on.
Total estimated build-to-suit commitments of $246.5 million, down from $418.8 million reported on October 30, 2024.
A prospective tenant shifted strategy after an unanticipated executive leadership change and declined a large build-to-suit transaction in the pipeline.
Of the $246.5 million, $125.4 million is for developments actively under construction and $121.1 million is additional development commitments.
CEO John Moragne, CFO Kevin Fennell and Brent Maedl will participate in Nareit REITworld 2024 in Las Vegas on November 19 and 20, 2024.
Air Products said directors David H.Y. Ho and Matthew H. Paull will retire and not stand for re-election at the 2025 Annual Meeting of Shareholders, and its board approved two new nominees, Bhavesh V. "Bob" Patel and Alfred Stern. The filing reports no financial results; for shareholders, the change affects board composition, which will remain at nine directors, six of whom will have been appointed in the last five years.
Ho and Paull notified the company on November 17, 2024, and both have served as directors since 2013
Retirements take effect immediately after the conclusion of the 2025 Annual Meeting
Nominees Patel and Stern would take their board seats as of the Annual Meeting date if elected
Patel is a former CEO of W.R. Grace and LyondellBasell; Stern is CEO and Executive Board Chairman of the OMV Group
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.